VX-809 is a CFTR modulator with EC50 of 0.1 μM. VX-809 increases chloride secretions by 14% in human bronchial epithelial cells. Unlike VX-770, VX-809 is not a CFTR potentiator, as acute addition of VX-809 has no effect on F508del-CFTR function. VX-809 has been shown to correct the folding and processing of CFTR in F508del mutation cells in vitro. Pharmacodynamic data showed that VX-809 improved CFTR function in at least one organ (sweat gland). VX-809 reduced elevated sweat chloride values in a dose-dependent manner (p=0.0013) that was statistically significant in the 100 and 200 mg dose groups. VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors. VX-809 is currently in a phase II study alone and in combination with VX-770 in cystic fibrosis (CF) patients with the F508del-CFTR mutation.
|Cell lines||FRT, HEK-293 and HBE cells|
|Preparation method||CFTR Immunoblot Analysis.
FRT, HEK-293, or HBE cells expressing CFTR or F508del-CFTR were incubated for 24 h at 37 °C with or without VX-809 in the assay media. After incubation, cells were harvested in ice-cold D-PBS solution (without calcium and magnesium) and pelleted at 1,000 × g at 4 °C. Cell pellets were lysed in 1% Nonidet P-40, 0.5% sodium deoxycholate, 200 mM NaCl, 10 mM Tris, pH 7.8, and 1 mM EDTA plus protease inhibitor mixture (1:250; Roche) for 30 min on ice. Lysates were spun for 10 min at 10,000 × g at 4 °C to pellet nuclei and insoluble material. Approximately 12 μg total protein was heated in Laemmli buffer with 5% β mercaptoethanol at 37 °C for 5 min and loaded onto a 3% to 8% Tris-acetate gel (Invitrogen). The gel was transferred to nitrocellulose and processed for Western blotting by using monoclonal CFTR antibody 769 (gift from John R. Riordan, University of North Carolina, Chapel Hill, NC) or polyclonal to GAPDH (Santa Cruz Biotechnology). Blots were developed by enhanced chemiluminescence. Quantification of the relative amounts of bands C and GAPDH was performed by using NIH ImageJ analysis of scanned films.
|Incubation time||48 h|
|Animal models||Male Sprague–Dawley rats model|
|Formulation||0.5% Tween80/0.5% methylcellulose/water|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 90 mg/mL|
|Source||Br J Pharmacol (2016). Figure 4. VX-809 (lumacaftor) was purchased from AbMole BioScience (Houston, USA)|
|Cell Lines||HeLa-F508del cells|
|Incubation Time||24 h|
|Results||VX-809 treatment induced maturation of CFTR F508del (Figure 4A) and inhibited NF-κB activity and IL-8 promoter activity (Figure 4C and 4D). HeLa-F508del cells transiently transfected with reporter system were corrected with VX-809, treated with vehicle or sulindac and inflammation was induced by TNF-α as shown figure 4B.|
Br J Pharmacol. 2016 Feb 19.
New use for an Old drug: COX-independent anti-inflammatory effects of sulindac in CF models.
VX-809 purchased from AbMole
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.
Van Goor F, et al. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8. PMID: 21976485.
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Clancy JP, et al. Thorax. 2012 Jan;67(1):12-8. PMID: 21825083.
|Related CFTR Products|
PPQ-102 is a potent CFTR inhibitor which can completely inhibited CFTR chloride current with IC 50 approximately 90 nM.
VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface.
IOWH032 is a synthetic CFTR inhibitor with IC50 of 1.01 μM in CHO-CFTR cell based assays. Phase 1/2.
CFTRinh-172 is a voltage-independent, selective CFTR inhibitor with Ki of 300 nM, showing no effects on MDR1, ATP-sensitive K+ channels, or a series of other transporters.
Lonidamine is a novel CFTR open channel blocker with an IC50 of 0.85 mM, which inhibits aerobic glycolysis in cancer cells.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.